Skip to Content

29th International Papillomavirus Conference

DCEG researchers present their work on HPV

Friday, August 22

10:45 AM – 12:15 PM
Concurrent Sessions/Public Health Sciences: Epidemiology
Lisa Mirabello, Ph.D., “Novel HPV16 genetic polymorphisms are associated with an increased risk of CIN3+ in women infected with European lineage (A) variants”

1:45 PM – 3:15 PM
Concurrent Sessions: Clinical Sciences/Clinical Screening, Julia Gage, Ph.D., co-chair

Concurrent Sessions/Public Health Sciences: Vaccines 1, Allan Hildesheim, Ph.D., co-chair
Mahboobeh Safaeian, Ph.D., “HPV16 antibody avidity following one and two doses of HPV16/18 vaccine: Results from the Costa Rica HPV16/18 Vaccine Trial (CVT)"

3:15 PM – 5:15 PM
Poster Session 1
Vikrant Sahasrabuddhe, Ph.D., “Evaluation of two urine-based HPV assays in comparison to cervical HPV detection and high-grade CIN among women attending a colposcopy clinic"

Saturday, August 23 

7:30 AM - 8:30 AM
Satellite Session 
Mahboobeh Safaeian, Ph.D., “Immunoepidemiologic correlates of vaccination with fewer than three HPV vaccine doses “ at the “Incomplete vaccination among target age adolescents: Need for completing series?” 

8:45 AM – 10:15 AM
Plenary 2: Natural History
Aimee Kreimer, Ph.D., "Oral HPV natural history and its progression to oropharyngeal cancer”

10:45 AM – 12:15 PM
Concurrent Sessions/Clinical Sciences: Head & Neck
Anil Chaturvedi, Ph.D., “Oral HPV infection among men and women in the United States, NHANES 2009-2012”

Concurrent Sessions/Public Health Sciences: Screening – Strategy, Mark Schiffman, M.D., M.P.H., co-chair

3:45 PM – 5:15 PM
Concurrent Sessions/Clinical Sciences: Screening and Guidelines
Hormudz Katki, Ph.D., “Using cervical precancer/cancer risks based on 1 million women to develop the 2012 US screening and management guidelines incorporating HPV testing”

Julia Gage, Ph.D., “Potential safety of primary HPV testing: Evidence from 1 million women undergoing HPV and Pap testing in routine cervical cancer screening since 2003 “Screening and Guidelines”

Sunday, August 24 

10:15 AM – 12:15 PM
Poster Session 3
Allan Hildesheim, Ph.D., “Impact of HPV 16/18 vaccination on prevalent infections and on recurrence after excisional treatment"

Hilary Robbins, M.S.P.H., "Immunogenicity assessment of HPV16/18 vaccine using glutathione S-transferase multiplex serology"

1:45 PM – 3:15 PM
Concurrent Sessions/Clinical Sciences: Cervix 1
Vikrant Sahasrabuddhe, Ph.D., “Improving cervical cancer prevention among HIV+ women using HPV-based biomarker assays: design and initial results from a multicentric study in India"

3:45 PM – 5:15 PM
Concurrent Sessions/Clinical Sciences: Cervix 2, Anil Chaturvedi, Ph.D., co-chair

11:15 AM – 12:15 PM
Public Health Sciences: Clinical and Screening
Nicolas Wentzensen, M.D., “Evaluation of P16/KI-67 cytology for detection of cervical precancers in HPV-vaccinated women”

Monday, August 25

7:30 AM – 8:30 AM
Satellite Symposium: HPV-related Cancer Genetics
Mahboobeh Safaeian, Ph.D., “Overview of session objectives and introduction of speakers"

Allan Hildesheim, Ph.D., “HLA associations in non-HPV viral cancers"

10:45 AM – 12:15 PM
Concurrent Sessions/Public Health Sciences: Vaccines 2
Krystle Lang Kuhs, Ph.D., “Reduced prevalence of vulvar HPV16/18 infection among women who received the bivalent vaccine: A nested analysis within the Costa Rica Vaccine Trial”